Luerken Lukas, Goetz Andrea, Mayr Vinzenz, Zhang Liang, Schlitt Alexandra, Haimerl Michael, Stroszczynski Christian, Schlitt Hans-Jürgen, Grube Matthias, Kandulski Arne, Einspieler Ingo
Department of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany.
Department of Diagnostic and Interventional Radiology, Klinikum Würzburg Mitte gGmbH, 97070 Würzburg, Germany.
Biomedicines. 2024 Dec 17;12(12):2870. doi: 10.3390/biomedicines12122870.
: To report on the first results of safety, efficacy, and outcome of CT-navigated stereotactic percutaneous electrochemotherapy (SpECT) in patients with primary and secondary liver malignancies. : This retrospective study included 23 consecutive lesions in 22 patients who underwent SpECT for primary and secondary malignant liver lesions with locally curative intention. The endpoints were primary technique efficacy (PTE), local tumor progression (LTP), time to progression (TTP), and occurrence of adverse events. : The mean maximum diameter of the treated lesions was 42 mm (range: 16 mm-72 mm). Eight lesions were hepatocellular carcinoma (34.8%), five lesions were colorectal liver metastases (21.7%), three lesions were cholangiocellular carcinoma (13.0%), and the other seven lesions were liver metastases from different primary cancers (30.4%). PTE was achieved for 22 lesions (95.7%). The mean follow-up time was 15 months (0-39 months). No LTP was observed. In six patients (27.3%), hepatic tumor progression was observed during follow-up with a mean TTP of 3.8 months (2-8 months). In 10 procedures (43.5%), minor complications (1 CIRSE Grade 2) and side effects occurred, but no major complications were observed. : SpECT seems to be a safe and effective new local treatment modality for primary and secondary liver malignancies.
报告CT引导下立体定向经皮电化学疗法（SpECT）治疗原发性和继发性肝脏恶性肿瘤患者的安全性、有效性及预后的初步结果。：这项回顾性研究纳入了22例患者的23个连续病灶，这些患者因原发性和继发性肝脏恶性病灶接受了具有局部治愈意图的SpECT治疗。观察终点为主要技术疗效（PTE）、局部肿瘤进展（LTP）、进展时间（TTP）及不良事件的发生情况。：治疗病灶的平均最大直径为42mm（范围：16mm - 72mm）。8个病灶为肝细胞癌（34.8%），5个病灶为结直肠癌肝转移瘤（21.7%），3个病灶为胆管细胞癌（13.0%），另外7个病灶为不同原发癌的肝转移瘤（30.4%）。22个病灶（95.7%）实现了PTE。平均随访时间为15个月（0 - 39个月）。未观察到LTP。6例患者（27.3%）在随访期间观察到肝肿瘤进展，平均TTP为3.8个月（2 - 8个月）。10例操作（43.5%）出现轻微并发症（1例CIRSE 2级）及副作用，但未观察到严重并发症。：SpECT似乎是一种治疗原发性和继发性肝脏恶性肿瘤安全有效的新的局部治疗方式。
